Cidara Appoints Frank Karbe as CFO to Propel Growth
Portfolio - People | Feb 18, 2025 | EIN
Cidara Therapeutics, a biotechnology firm, has appointed Frank Karbe as its new Chief Financial Officer (CFO), effective February 24, 2025. Karbe, who brings over 25 years of leadership experience in the biopharma industry, succeeds Preetam Shah, who will serve as a consultant for the company following his departure. The decision aligns with Cidara's strategic initiatives as it progresses drug developments including its lead DFC candidate, CD388. CEO Jeffrey Stein emphasizes Karbe's potential to support Cidara in becoming a multi-billion-dollar enterprise. Karbe is recognized for his previous successful tenure at Better Therapeutics and as CFO of Exelixis. Cidara's DFC platform and lead candidate, CD388, aim to provide universal influenza prevention, having started Phase 2b trials in September 2024. The company looks forward to leveraging Karbe's expertise to drive growth, evidenced by the inducement awards aligning with Nasdaq Listing rules, underlining the strategic importance of his appointment.
Sectors
- Biotechnology
- Pharmaceuticals
- Healthcare
Geography
- United States – The article involves Cidara Therapeutics, a company headquartered in San Diego, California.
Industry
- Biotechnology – Cidara is a biotechnology company focusing on drug-Fc conjugate immunotherapies, making the biotech sector highly relevant.
- Pharmaceuticals – The development of antiviral drugs and clinical trials are central to the pharmaceuticals industry, reflecting Cidara's core operations.
- Healthcare – The focus on treatments for serious diseases and influenza prevention situates Cidara within the broader healthcare sector.
Financials
- 172,500 shares – Inducement stock awards to Frank Karbe as part of the Cidara 2020 Inducement Incentive Plan.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Cidara Therapeutics | Target Company | Company | A biotechnology company developing DFC immunotherapies. |
| Frank Karbe | Incoming CFO | Person | Newly appointed CFO with extensive biopharma leadership experience. |
| Preetam Shah | Outgoing CFO | Person | Outgoing CFO, transitioning to a consulting role. |
| Jeffrey Stein | CEO of Cidara | Person | CEO of Cidara Therapeutics. |
| LifeSci Advisors | Investor Relations | Company | Handles investor contact for Cidara. |
| LifeSci Communications | Media Relations | Company | Handles media contact for Cidara. |